Answers are grounded in this paper and cite their sources.
Background Paraneoplastic neurological syndromes (PNS) are immune-mediated disorders associated with cancer and often precede tumor diagnosis. Identification of novel neural autoantigens may facilitate diagnosis and treatment. Methods Sera or cerebrospinal fluid (CSF) from six patients showing a similar uncharacterized immunofluorescence staining pattern on rat hippocampal sections were collected. The target antigen was identified by immunoprecipitation and mass spectrometry and validated using established immunoassays. Results N-terminal EF-hand calcium-binding protein 1 (NECAB1) was revealed as target of the autoantibodies. Antigen identification was validated by competitive tissue IIFA, CBA, Western blot and line blot with the recombinant antigen. No reactivity was observed in CBA and line blot with 100 healthy controls or CBA with 303 disease controls. All five clinically characterized patients had breast or lung cancer and presented with limbic encephalitis ( n = 3), cerebellar ataxia with cognitive decline ( n = 1), or sensory-motor neuronopathy ( n = 1). Conclusions NECAB1 represents a novel autoantibody target in autoimmune neurological syndromes associated with lung or breast cancer. Samples from patients with suspected neurological autoimmune disorder showing the specific hippocampal interneuron IIFA pattern should be analyzed for NECAB1 autoantibodies by CBA or line blot and cancer screening should be considered.
No takes yet. Share an insight, caveat, or question.
Scharf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: